pioglitazone and triazoles
pioglitazone has been researched along with triazoles in 44 studies
Research
Studies (44)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (15.91) | 29.6817 |
2010's | 37 (84.09) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Ahrén, B | 2 |
Akita, N; Fukutomi, T; Gonzalez, FJ; Hossain, MA; Kimura, G; Ogata, M; Staels, B; Suzuki, S; Tsujita, M; Yokoyama, S | 1 |
Gallen, IW; Lumb, AN | 1 |
Argyrakopoulou, G; Doupis, J | 1 |
Mikhail, N | 1 |
Alexander, CM; Chapell, R; Gould, AL | 1 |
Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA | 1 |
Birnbaum, Y; Keyes, KT; Lin, Y; Perez-Polo, JR; Ye, Y; Zhang, C | 1 |
Bergenstal, RM; Macconell, L; Malloy, J; Malone, J; Porter, LE; Walsh, B; Wilhelm, K; Wysham, C; Yan, P | 1 |
Meier, JJ; Nauck, MA | 1 |
Bailey, CJ; Flatt, PR; Green, BD | 1 |
Boulton, DW; Griffen, SC; Kasichayanula, S; LaCreta, FP; Li, T; Liu, X; Pfister, M; Shyu, WC; Zhang, W | 1 |
Baggio, LL; Drucker, DJ; Grynpas, MD; Kyle, KA; Willett, TL | 1 |
Amatruda, JM; Golm, GT; Kaufman, KD; Meehan, AG; Shockey, GR; Steinberg, H; Teng, R; Thakkar, PR; Williams-Herman, DE; Yoon, KH | 1 |
Best, JH; Garrison, LP; Li, Y; Malloy, J; Peyrot, M; Rubin, RR; Yan, P | 1 |
Bergenstal, R; Malloy, J; Malone, J; Taylor, K; Walsh, B; Wysham, C; Yan, P | 1 |
DeYoung, MB; Herbert, P; MacConell, L; Sarin, V; Trautmann, M | 1 |
Engel, SS; Goldstein, BJ; Kaufman, KD; Lee, MA; Pérez-Monteverde, A; Seck, T; Sisk, CM; Williams-Herman, DE; Xu, L | 1 |
Engel, SS; Goldstein, BJ; Golm, GT; Hussain, S; Katz, L; Kaufman, KD; O'Neill, EA; Wainstein, J; Xu, L | 1 |
Jermendy, G | 1 |
Abdollahi, M; Ahmadi, A; Baeeri, M; Rezvanfar, MA; Saadi, HA | 1 |
Cho, JH; Ham, DS; Kim, ES; Kim, JW; Park, HS; Sun, C; Yeom, JA; Yoon, KH | 1 |
Masmiquel Comas, L; Nicolau Ramis, J | 1 |
Boardman, MK; Chan, M; Cuddihy, RM; González, JG; Hanefeld, M; Kumar, A; Russell-Jones, D; Wolka, AM | 1 |
Best, JH; DeYoung, MB; Gaebler, JA; Guillermin, AL; Lloyd, A; Samyshkin, Y | 1 |
Goldstein, BJ; Golm, GT; Kaufman, KD; Lee, M; O'Neill, EA; Steinberg, H; Teng, R; Yoon, KH | 1 |
Kadokura, T; Keirns, J; Krauwinkel, WJ; Smulders, RA; van Dijk, J; Veltkamp, SA; Zhang, W | 1 |
Isogawa, A; Iwamoto, M; Koike, K; Ohki, T; Ohsugi, M; Omata, M; Tagawa, K; Toda, N; Yoshida, H | 1 |
Inazumi, T; Kimura, M; Komatsu, Y; Kondo, Y; Nakamura, A; Tajima, K; Takihata, M; Tamura, H; Terauchi, Y; Yamada, M; Yamazaki, S | 1 |
Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Franzetti, IG; Maffioli, P; Piccinni, MN; Querci, F | 2 |
Ahrén, B; Alba, M; Goldstein, BJ; Guan, Y; Inzucchi, SE; Kaufman, KD; Mallick, M; O'Neill, EA; Williams-Herman, DE; Xu, L | 1 |
Moniri, NH; Ryan, GJ; Smiley, DD | 1 |
Cander, S; Cinkilic, N; Ersoy, C; Gul, CB; Oz Gul, O; Tuncel, E; Vatan, O; Yılmaz, D | 1 |
Chou, MZ; Fonseca, VA; Goldstein, BJ; Golm, GT; Henry, RR; Kaufman, KD; Langdon, RB; Staels, B; Steinberg, H; Teng, R | 1 |
Li, H; Lu, J; Zang, J | 1 |
Bethel, MA; Califf, RM; Green, JB; Holman, RR; Kaufman, KD; Paul, SK; Ring, A; Shapiro, DR | 1 |
Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J | 1 |
Iwamura, T; Kainoh, M; Kawai, K; Kumagai, H; Nakaki, J; Nitta, A; Okazaki, S; Sakami, S; Sato, M; Sekiya, Y; Takahashi, T; Yagi, M | 1 |
Ekoé, JM; Kuritzky, L; Landó, LF; Mancillas-Adame, L; Umpierrez, G | 1 |
Thompson, AM; Trujillo, JM | 1 |
Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M | 1 |
Abdel Moety, G; Al Mohammady, M; El-khayat, W; Hamed, D | 1 |
Reviews
12 review(s) available for pioglitazone and triazoles
Article | Year |
---|---|
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Pioglitazone; Piperidines; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Uracil | 2009 |
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Topics: Adamantane; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.
Topics: Bayes Theorem; Confidence Intervals; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2009 |
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Metformin; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sensitivity and Specificity; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2009 |
Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2010 |
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
Topics: Adult; Blood Glucose; Capsules; Diabetes Mellitus, Type 2; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Lactic Acid; Peptides; Pioglitazone; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
Topics: Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Evidence-Based Medicine; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2013 |
Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Metformin; Outcome Assessment, Health Care; Pioglitazone; Proinsulin; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2014 |
Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2015 |
Trials
20 trial(s) available for pioglitazone and triazoles
Article | Year |
---|---|
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Resistin; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Tumor Necrosis Factor-alpha | 2010 |
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Computer-Assisted; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid A; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2010 |
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
Topics: Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2011 |
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2011 |
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Female; Health Status; Humans; Hypoglycemic Agents; Male; Mental Health; Middle Aged; Patient Satisfaction; Peptides; Pioglitazone; Pyrazines; Quality of Life; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2011 |
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2011 |
Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2011 |
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2012 |
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
Topics: Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2012 |
No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
Topics: Adolescent; Adult; Area Under Curve; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Triazoles | 2012 |
Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucose Clamp Technique; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucagon; Glucagon-Secreting Cells; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Middle Aged; Pioglitazone; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2014 |
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Pyrazines; Research Design; Sitagliptin Phosphate; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osmotic; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Thiophenes; Treatment Outcome; Triazoles; Weight Loss | 2014 |
Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.
Topics: 1-Deoxynojirimycin; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Female; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sorbitol; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2015 |
A randomized controlled trial of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone for clomifene-citrate-resistant polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Egypt; Female; Fertility Agents, Female; Humans; Infertility, Female; Intention to Treat Analysis; Letrozole; Metformin; Nitriles; Ovulation; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Prospective Studies; Thiazolidinediones; Triazoles | 2016 |
Other Studies
12 other study(ies) available for pioglitazone and triazoles
Article | Year |
---|---|
On the mechanism for PPAR agonists to enhance ABCA1 gene expression.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Cell Line, Tumor; Fenofibrate; Fibroblasts; Gemfibrozil; Gene Expression Regulation; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pioglitazone; PPAR delta; PPAR gamma; Propionates; Thiazoles; Thiazolidinediones; Triazoles | 2009 |
Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Hepatocyte Nuclear Factor 1-alpha; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2009 |
The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.
Topics: Animals; Blood Glucose; Blotting, Western; Body Weight; Culture Media; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dipeptidyl-Peptidase IV Inhibitors; Eicosanoids; Glucagon-Like Peptide 1; Hypertrophy, Left Ventricular; Hypoglycemic Agents; In Vitro Techniques; Mice; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Organ Size; Phospholipases A2; Pioglitazone; Prostaglandin-Endoperoxide Synthases; Protective Agents; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2010 |
Individualised incretin-based treatment for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2010 |
Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Dipeptidyl Peptidase 4; Female; Hypoglycemic Agents; In Vitro Techniques; Male; Mice; Mice, Knockout; Obesity; Ovariectomy; Pioglitazone; PPAR gamma; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2011 |
Mechanistic links between oxidative/nitrosative stress and tumor necrosis factor alpha in letrozole-induced murine polycystic ovary: biochemical and pathological evidences for beneficial effect of pioglitazone.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aromatase Inhibitors; Estradiol; Female; Hypoglycemic Agents; Letrozole; Lipid Peroxidation; Nitriles; Oxidative Stress; Pioglitazone; Polycystic Ovary Syndrome; PPAR gamma; Progesterone; Prostaglandins E; Rats; Rats, Wistar; Testosterone; Thiazolidinediones; Triazoles; Tumor Necrosis Factor-alpha | 2012 |
Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Cell Proliferation; Diabetes Mellitus, Experimental; Fasting; Glucose Tolerance Test; Homeostasis; Insulin-Secreting Cells; Ki-67 Antigen; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Organ Size; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2011 |
[The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].
Topics: Animals; Breast Neoplasms; Calcitonin; Carcinoma, Medullary; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Disease Susceptibility; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Infections; Liraglutide; Pancreatitis; Pharmacovigilance; Pioglitazone; Pyrazines; Risk Assessment; Safety-Based Drug Withdrawals; Sitagliptin Phosphate; Species Specificity; Thiazolidinediones; Thyroid Neoplasms; Triazoles; Urinary Bladder Neoplasms | 2012 |
Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
Topics: Adult; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Humans; Hypoglycemic Agents; Long-Term Care; Male; Markov Chains; Middle Aged; Models, Theoretical; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; United States; Venoms | 2012 |
The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.
Topics: Adult; Alanine Transaminase; Blood Glucose; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Drug Evaluation; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Inflammation; Liraglutide; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Odds Ratio; Pioglitazone; Platelet Count; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2012 |
Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: a cross-sectional, observational pilot study.
Topics: Aged; Blood Glucose; Chromosome Aberrations; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Micronuclei, Chromosome-Defective; Middle Aged; Pilot Projects; Pioglitazone; Pyrazines; Rosiglitazone; Sister Chromatid Exchange; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Administration, Oral; Animals; Azepines; Carbenoxolone; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Obesity; Pioglitazone; Thiazolidinediones; Triazoles | 2014 |